

2020

Microbiota: the missing link in the etiology of inflammatory bowel disease

Micu Ioan Sergiu

EMERGENCY HOSPITAL OF CONSTANTA, DEPARTMENT OF GASTROENTEROLOGY, CONSTANTA, ROMANIA

Madalina Elena Manea

EMERGENCY HOSPITAL OF CONSTANTA, DEPARTMENT OF DIABETES MELLITUS AND NUTRITIONAL DISEASES, CONSTANTA, ROMANIA

Musat Marilena

EMERGENCY HOSPITAL OF CONSTANTA, DEPARTMENT OF GASTROENTEROLOGY, CONSTANTA, ROMANIA

Dumitru Andrada

EMERGENCY HOSPITAL OF CONSTANTA, DEPARTMENT OF GASTROENTEROLOGY, CONSTANTA, ROMANIA

Popoiag Roxana Emanuela

EMERGENCY HOSPITAL OF CONSTANTA, FACULTY OF MEDICINE, CONSTANTA, ROMANIA



Part of the [Endocrinology, Diabetes, and Metabolism Commons](#), [Gastroenterology Commons](#), [Infectious Disease Commons](#), and the [Integrative Medicine Commons](#)

Recommended Citation

Ioan Sergiu, Micu; Manea, Madalina Elena; Marilena, Musat; Andrada, Dumitru; and Roxana Emanuela, Popoiag (2020) "Microbiota: the missing link in the etiology of inflammatory bowel disease," *Journal of Mind and Medical Sciences*: Vol. 7 : Iss. 1 , Article 6.

DOI: 10.22543/7674.71.P2933

Available at: <https://scholar.valpo.edu/jmms/vol7/iss1/6>

This Review Article is brought to you for free and open access by ValpoScholar. It has been accepted for inclusion in *Journal of Mind and Medical Sciences* by an authorized administrator of ValpoScholar. For more information, please contact a ValpoScholar staff member at scholar@valpo.edu.

Microbiota: the missing link in the etiology of inflammatory bowel disease

Micu Ioan Sergiu¹, Manea Madalina Elena², Musat Marilena¹, Dumitru Andrada¹, Popoiag Roxana Emanuela³

¹EMERGENCY HOSPITAL OF CONSTANTA, DEPARTMENT OF GASTROENTEROLOGY, CONSTANTA, ROMANIA

²EMERGENCY HOSPITAL OF CONSTANTA, DEPARTMENT OF DIABETES MELLITUS AND NUTRITIONAL DISEASES, CONSTANTA, ROMANIA

³OVIDIUS UNIVERSITY OF CONSTANTA, FACULTY OF MEDICINE, CONSTANTA, ROMANIA

ABSTRACT



Within its twisted and tight walls, where a hostile and arid environment prevails, the lumen of the digestive tract nests a true microuniverse called the microbiota. The existing relationship between humans and these microorganisms is one in which both benefit, creating a condition called Eubiosis.

The dynamic relationship existing between the microbiota and the human body can be affected at various times, leading to an imbalance that may have important implications on health and generating a condition called Disbiosis.

Recent studies have highlighted possible links between several diseases with incompletely elucidated etiology and disturbances of the microbiota. In this review we aim to analyze the existing relationship between the imbalances of the gastrointestinal flora and the etiopathogeny inflammatory bowel diseases, a group of diseases whose incidence has increased considerably in recent years.

Category: Review

Received: November 18, 2019

Accepted: February 12, 2020

Keywords:

The Microbiota, Dysbiosis, Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis.

*Corresponding author:

Micu Ioan Sergiu, Emergency Hospital of Constanta, Department of Gastroenterology, Constanta, Romania
E-mail: micuioansergiu@yahoo.com

Introduction

There are over 100 trillion microorganisms at the level of the gastrointestinal tract (GI), which make up a complex biosystem called the microbiota. The composition of the microbiota is vast, containing entities belonging to all domains of life: Eukarya Bacteria and Archaea. Broadly, the main components that make up the structure of this microuniverse belong to the bacteria group and are represented by species from four major phyla: Actinobacteria, Proteobacteria, Bacteroidetes, and Firmicutes [1].

Between the human body and the microbiota is established a dynamic and very complex relationship, alteration of this biosystem sometimes causing adverse consequences on the health status. The functions of the GI flora depend on its composition/ biocharacteristics of the species, having implications for the following processes: modulation of the digestion process, regulation of immunity, biosynthesis of vitamins, and harvesting energy [2-6].

Alteration of the structure - and thus of the function- of the microbiota bears the name of dysbiosis, a condition linked to numerous pathological conditions such as type 2 diabetes, obesity, cancer, autoimmune disorders, and allergies [7-13].

Inflammatory bowel diseases (IBD) represent a set of gastrointestinal disorders with incompletely elucidated etiology, which includes two distinct clinical and pathological entities: Crohn's disease (CD) and Ulcerative Colitis (UC). IBD are characterized by inflammatory impairment of the digestive tract, which present an undulating evolution consisting of periods of remission and relapse [14].

Discussions

IBD: Overview

IBD usually refers to two chronic pathological conditions, represented by Crohn's Disease and Ulcerative Colitis. The main feature of IBD consists of inflammation, which can be localized at any level of the digestive tract.

The clinical manifestations of these conditions are dominated by gastrointestinal symptoms, ranging from diarrhea to malabsorption, loss of nutrients as well as digestive bleeding due to inflammation. These symptoms are often accompanied by abdominal pain, severity ranging from mild to severe (life-threatening) according to the degree of the local/ intestinal inflammatory process. The inflammation has generally a chronic clinical evolution, marked by an alternation of remissions and exacerbations [15].

The incidence and prevalence of these diseases are globally increasing, the countries with the highest values being those that are highly developed and industrialized, such as North America and Northern Europe. Recent investigations show that the incidence is stabilising or slightly decreasing in developed countries, being conversely rapidly increasing in countries that are in the full process of industrialization, urbanization, and westernization, such as in Asia, South America, and Africa [16,17].

Microbiota and IBD

The etiology and pathophysiology of IBD are not completely elucidated. IBD results from the complex interaction of environmental and intestinal microbial factors within a organism that has a genetic susceptibility, which ultimately results in an abnormal immune response partly disconnected from its own regulatory mechanisms (Figure 1) [18].




Figure 1. Interaction of factors that are contributing to IBD occurrence.

Recently, more emphasis has been placed on the interaction between the intestinal flora and the host's immune system, the presence of microorganisms at intestinal level being a key element (if not mandatory) in the genesis of this pathology [19]. The loss of tolerance for intestinal bacteria (which triggers an immune response) may

be one of the main explanations for pathogenesis of these diseases [20]. This pathological process may be strongly influenced by alteration in the composition, structure, and function of the gut microbiota, a condition referred to as dysbiosis. These assumptions are indirectly supported by the positive results (good control of intestinal inflammation) obtained after administration of gut flora regulators such as probiotics, prebiotics, and antibiotics [21].

An important quantitative change found in the intestinal flora of IBD patients is reduction of the bacterial load and reduction of its diversity [22], the reduction of diversity being described within the same individual, in the same digestive segment, and between the areas affected by the inflammatory process and the healthy ones [23].

The main qualitative changes in the composition of the microbiota are represented in IBD patients by increases and decreases of certain bacterial populations. An important change in this balance is represented by an increase of the harmful bacteria and a reduction in the population of bacteria with a protective role on the digestive tract.

The reduction of protective bacterial species is usually related to the following populations: gram-positive bacterias (species from phyla Firmicutes), butyrate-producing bacterias (*Roseburia*, *Faecalibacterium prausnitzii*), and general protective species (from the genus *Bifidobacterium*) [24, 25]. These changes are significant because all of these species play an important role in maintaining the intestinal homeostasis through a range of functions, such as: production of short chain fatty acids, strengthening the intestinal barrier, reduction of local and systemic inflammation, and protection from pathogenic species of bacteria. The protective role of these microorganisms in the pathophysiology of IBD is supported by multiple research studies. As an example, some studies have shown that chemically induced intestinal inflammation induces clinical manifestations that are more pronounced in mice with a sterile gut, than in conventional mice having a digestive tract populated with microorganisms [26].

The populations of harmful bacterial species found to be increased in IBD patients are represented by several gram-negative bacteria (such as *Proteobacteria*, *Pasteurellaceae*) and various opportunistic pathogens (*Escherichia coli*, *Fusobacteria*, etc.), all these species having as the main characteristic a proinflammatory effect that is present both locally and systemically [27].

The manner in which the altered bacterial population interacts with the internal environment (leading thus to pathogenesis of IBD) is incompletely elucidated, but their presence is quite well documented. In support of this, a recent study proved that mice with a sterile gut do not develop colitis, and this is possible only through insertion of fecal matter containing bacteria [28].

Several mechanisms have been proposed to explain the role of an altered intestinal microbiota in the development of

the inflammatory process that is associated with inflammatory bowel diseases. Such mechanisms are represented by an increase in intestinal permeability leading to bacterial translocation, synthesis of toxic products that migrate into the internal environment due to increased intestinal permeability (generating thus endotoxemia), disturbance of intestinal cell's endoplasmic reticulum homeostasis, and oxidative stress.

The increase in intestinal permeability could be a consequence of reduction of the population of short-chain fatty acid-producing bacteria. Endotoxemia is caused by production of toxic substances by bacteria (such as *Escherichia coli*, Proteobacteria, Pasteurellaceae), migration of toxic compounds being favored by the deficient intestinal barrier. The functional alteration of the endoplasmic reticulum can be induced by different bacterial species' production of various toxic substances, which enter the intestinal epithelial cells and are able to interfere with the functionality of the endoplasmic reticulum (e.g. *Escherichia coli*). Some species of bacteria (*Escherichia coli*, *Helicobacter pylori*) can produce reactive oxygen, causing oxidative stress in the digestive tract and thus contributing to the maintenance of the inflammatory process [29].

In addition to bacterial abnormalities described for IBD, it appears that intestinal viral and fungal populations also exhibit a number of alterations, even if they represent an extremely small part of the microbiota composition.

Regarding the changes found in the fungal population, species belonging to the classes Basidiomycota, *Candida albicans*, and Ascomycota have been found to be increased, while the *Saccharomyces cerevisiae* population seems to be decreased. The role of the fungal implication in pathophysiology of IBD is incompletely elucidated, literature data showing that molecules present on the fungal wall surface (beta-glucans, chitin) are able to trigger the innate immune response and thus to contribute to maintenance of the inflammatory process [30].

The intestinal viral population of IBD patients is characterized by a greater variability, with the expansion of the bacteriophage-type population [31]. A recent study revealed an increased bacteriophages class from the order Caudovirales. At the level of the digestive tract, the bacteriophages contribute not only to the maintenance of bacterial homeostasis but also to the modulation of the immune response. Even so, there is currently not enough evidence to suggest that intestinal viral microbiota play an essential role in the development and evolution of IBD [32].

Highlights

At the level of the gastrointestinal tract there are over 100 trillion microorganisms that make up the microbiota.

Alteration of the structure and the function of the microbiota, known as dysbiosis, has been linked to

numerous pathological conditions such as type 2 diabetes, obesity, cancer, autoimmune disorders, and allergies.

Inflammatory bowel diseases result from the complex interaction of environmental and intestinal microbial factors, within an organism that generally has a genetic susceptibility.

The loss of tolerance for intestinal bacteria (which often triggers an immune response) may be one of the main explanations in the pathogenesis of this disease.

Some changes encountered in composition of the microbiota are characterised by an increase/ abundance of the harmful bacteria, and a reduction in the population of bacteria with a protective role on the digestive tract.

Conclusions

IBD is a group of diseases whose incidence is still increasing. With multiple complications and comorbidities, and often debilitating clinical manifestations, IBD causes a marked decrease in patients' quality of life. The etiology and pathogenesis of these diseases are incompletely elucidated, the new researches emphasizing an important role of the gut microbiota in the occurrence and progression of such inflammatory diseases. Modulation of the composition and structure of the commensal flora through multiple therapeutic pathways (like probiotics, prebiotics, antibiotics, and fecal transplantation) can determine positive results and provide a better perspective for these digestive conditions.

References

1. Thursby E, Juge N. Introduction to the human gut microbiota. *Biochem J.* 2017;474(11):1823–1836. doi:10.1042/BCJ20160510
2. Vancamelbeke M, Vermeire S. The intestinal barrier: a fundamental role in health and disease. *Expert Rev Gastroenterol Hepatol.* 2017;11(9):821–834. doi:10.1080/17474124.2017.1343143
3. Rowland I, Gibson G, Heinken A, et al. Gut microbiota functions: metabolism of nutrients and other food components. *Eur J Nutr.* 2018;57(1):1–24. doi:10.1007/s00394-017-1445-8
4. Blaut M. Gut microbiota and energy balance: role in obesity. *Proc Nutr Soc.* 2015;74(3):227–234. doi:10.1017/S0029665114001700
5. Lazar V, Ditu LM, Pircalabioru GG, et al. Aspects of Gut Microbiota and Immune System Interactions in Infectious Diseases, Immunopathology, and Cancer. *Front Immunol.* 2018;9:1830. Published 2018 Aug 15. doi:10.3389/fimmu.2018.01830
6. LeBlanc JG, Milani C, de Giori GS, Sesma F, van Sinderen D, Ventura M. Bacteria as vitamin suppliers to their host: a gut microbiota perspective.

- Curr Opin Biotechnol.* 2013; 24(2): 160–168. doi:10.1016/j.copbio.2012.08.005
7. De Luca F, Shoenfeld Y. The microbiome in autoimmune diseases. *Clin Exp Immunol.* 2019;195(1):74–85. doi:10.1111/cei.13158
 8. Mariona Pascal et al. *Microbiome and Allergic Diseases.* 2018. doi: 10.3389/fimmu.2018.01584
 9. Ma J, Li H. The Role of Gut Microbiota in Atherosclerosis and Hypertension. *Front Pharmacol.* 2018;9:1082. Published 2018 Sep 25. doi: 10.3389/fphar.2018.01082
 10. Dahmus JD, Kotler DL, Kastenber DM, Kistler CA. The gut microbiome and colorectal cancer: a review of bacterial pathogenesis. *J Gastrointest Oncol.* 2018;9(4):769–777. doi:10.21037/jgo.2018.04.07
 11. Suceveanu AI, Stoian AP, Parepa IR, Voinea C, Hainarosie R, Manuc D, Nitipir C, Mazilu L, Suceveanu AP. Gut Microbiota Patterns in Obese and Type 2 Diabetes (T2D) Patients from Romanian Black Sea Coast Region. *CHIMIA (Bucharest).* 2018;69(8): 2260-2267.
 12. Mazilu L, Ciufu N, Gălan M, Suceveanu AI, Suceveanu AP, Parepa IR, Tofolean DE. Posttherapeutic Follow-up of Colorectal Cancer Patients Treated with Curative Intent. *Chirurgia* 2012; 107(1):55-58.
 13. Suceveanu AI, Suceveanu AP, Voinea FI, Mazilu L, Mixici F, Adam T. Introduction of cytogenetic tests in CRC screening. Introduction of cytogenetic tests in CRC screening. *J Gastrointest Liver Dis.* 2009; 18(1):33-38.
 14. Abraham C, Cho JH. Inflammatory Bowel Disease. *N Engl J Med.* 2009; 361: 2066-2078. doi: 10.1056/NEJMra0804647
 15. Hendrickson BA, Gokhale R, Cho JH. Clinical aspects and pathophysiology of inflammatory bowel disease. *Clin Microbiol Rev.* 2002; 15(1): 79–94. doi:10.1128/cmr.15.1.79-94.2002
 16. Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. *Lancet.* 2018;390(10114):2769–2778. doi: 10.1016/S0140-6736(17)32448-0
 17. Mozdiak E, O'Malley J, Arasaradnam R. Inflammatory bowel disease. *BMJ.* 2015;351:h4416. Published 2015 Sep 24. doi:10.1136/bmj.h4416
 18. Anca Trifan et al. Gastroenterologie si Hepatologie Clinica. Editura Medicala (Bucharest). 2018; 288-311.
 19. Lane ER, Zisman TL, Suskind DL. The microbiota in inflammatory bowel disease: current and therapeutic insights. *J Inflamm Res.* 2017;10:63–73. Published 2017 Jun 10. doi:10.2147/JIR.S116088
 20. Zuo T, Ng SC. The Gut Microbiota in the Pathogenesis and Therapeutics of Inflammatory Bowel Disease. *Front Microbiol.* 2018; 9: 2247.. doi: 10.3389/fmicb.2018.02247
 21. Macfarlane GT, Blackett KL, Nakayama T, Steed H, Macfarlane S. The gut microbiota in inflammatory bowel disease. *Curr Pharm Des.* 2009;15(13):1528–1536. doi:10.2174/138161209788168146
 22. Manichanh C, Rigottier-Gois L, Bonnaud E, et al. Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach. *Gut.* 2006;55(2):205–211. doi:10.1136/gut.2005.073817
 23. Popoiag RE, Pantea-Stoian A, Suceveanu AP, Suceveanu AI, Mazilu L, Parepa IR, Serban LM, Paunica M, Motofei C, Braticevici CF. The relationship between gut microbiota and spontaneous bacterial peritonitis in patients with liver cirrhosis - a literature review. *J Mind Med Sci.* 2019; 6(1): 26-30. doi: 10.22543/7674.61.P2630
 24. Sokol H, Seksik P, Furet JP, et al. Low counts of *Faecalibacterium prausnitzii* in colitis microbiota. *Inflamm Bowel Dis.* 2009;15(8):1183–1189. doi:10.1002/ibd.20903
 25. Frank DN, Robertson CE, Hamm CM, et al. Disease phenotype and genotype are associated with shifts in intestinal-associated microbiota in inflammatory bowel diseases. *Inflamm Bowel Dis.* 2011;17(1):179–184. doi:10.1002/ibd.21339
 26. Kitajima S, Morimoto M, Sagara E, Shimizu C, Ikeda Y. Dextran sodium sulfate-induced colitis in germ-free IQI/Jic mice. *Exp Anim.* 2001;50(5):387–395. doi:10.1538/expanim.50.387
 27. Stanescu AMA, Grajdeanu IV, Iancu MA, et al. Correlation of Oral Vitamin D Administration with the Severity of Psoriasis and the Presence of Metabolic Syndrome. *Revista de chimie* 2018;69(7):1668-1672.
 28. Kennedy RJ, Hoper M, Deodhar K, Erwin PJ, Kirk SJ, Gardiner KR. Interleukin 10-deficient colitis: new similarities to human inflammatory bowel disease. *Br J Surg.* 2000;87(10):1346–1351. doi:10.1046/j.1365-2168.2000.01615.x
 29. Cao SS. Cellular Stress Responses and Gut Microbiota in Inflammatory Bowel Disease. *Gastroenterol Res Pract.* 2018; 2018: 7192646. Published 2018 Jun 20. doi:10.1155/2018/7192646
 30. Sokol H, Leducq V, Aschard H, et al. Fungal microbiota dysbiosis in IBD. *Gut.* 2017;66(6):1039–1048. doi:10.1136/gutjnl-2015-310746.

31. Pérez-Brocal V, García-López R, Vázquez-Castellanos JF, et al. Study of the viral and microbial communities associated with Crohn's disease: a metagenomic approach. *Clin Transl Gastroenterol.* 2013; 4(6): e36. doi: 10.1038/ctg.2013.9
32. Wagner J, Maksimovic J, Farries G, et al. Bacteriophages in gut samples from pediatric Crohn's disease patients: metagenomic analysis using 454 pyrosequencing. *Inflamm Bowel Dis.* 2013; 19(8): 1598–1608. doi: 10.1097/MIB.0b013e318292477c